The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global fractional flow reserve market is expected to exhibit a CAGR of 12.1% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Fractional flow reserve (FFR) is used in cardiac catheterization to measure pressure differences across coronary artery stenosis. It determines the ratio between the maximum achievable blood flow in a diseased coronary artery and the theoretical maximum flow in a normal coronary artery. It has minute guidewires that can efficiently penetrate through arteries and help surgeons decide whether further surgical procedures, such as stenting or angioplasty, are required. At present, healthcare providers around the world rely on FFR as it is cost-effective and helps save lives while avoiding unnecessary surgical procedures.
According to the United Nations (UN) ‘World Population Ageing Report’, the global geriatric population (aged 60 years and above) was 962 Million in 2017 and is anticipated to reach 2.1 Billion by 2050. The aging population represents one of the major factors strengthening the FFR market growth, as older adults are more vulnerable to cardiovascular diseases (CVDs). Apart from this, high BMI, hypertension, rapid urbanization, physical inactivity, increasing consumption of fast food, and high blood sugar and cholesterol levels are some of the other leading risk factors for heart diseases and stroke, which in turn is escalating the demand for FFR across the globe. Furthermore, according to an article by the Society for Cardiovascular Angiography and Interventions (SCAI) published in May 2019, FFR offers valuable insights post angiography and impacts the treatment plans and outcomes among patients with the acute coronary syndrome (ACS) and stable coronary artery disease (CAD). Increasing research regarding the benefits of FFR is anticipated to accelerate its adoption among healthcare professionals.
IMARC Group provides an analysis of the key trends in each sub-segment of the global fractional flow reserve market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, application and end user.
Breakup by Product:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, ACIST Medical Systems Inc. (Bracco S.p.A.), Boston Scientific Corporation, CathWorks Ltd., Heartflow Inc., Koninklijke Philips N.V., Medis Medical Imaging Systems B.V., Opsens Inc., Pie Medical Imaging B.V. (Esaote Group), Siemens Healthineers AG and Terumo Medical Corporation.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, ACIST Medical Systems Inc. (Bracco S.p.A.), Boston Scientific Corporation, CathWorks Ltd., Heartflow Inc., Koninklijke Philips N.V., Medis Medical Imaging Systems B.V., Opsens Inc., Pie Medical Imaging B.V. (Esaote Group), Siemens Healthineers AG and Terumo Medical Corporation|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at